Literature DB >> 371597

Timolol maleate: efficacy and safety.

T J Zimmerman, M A Kass, M E Yablonski, B Becker.   

Abstract

A randomized, double-masked trial of various concentrations of timolol maleate ophthalmic solution (0.1%, 0.25%, 0.5%, and 1.0%) vs placebo demonstrated that all concentrations of timolol effectively lowered intraocular pressure (IOP). A 0.5% solution of timolol was as effective in reducing IOP as the 1.0% concentration. Blood pressure, visual acuity, and pupillary diameter were not altered significantly by any concentration of timolol tested during this study. There was a dose-dependent decrease in resting pulse rate with increasing concentrations of timolol. No objective signs of drug intolerance were found on external ocular examination, nor were any subjective symptoms elicited on questioning the subjects. Timolol applied topically twice daily in concentrations of 0.1% to 0.5% appeared to be an effective and safe ocular hypotensive agent.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 371597     DOI: 10.1001/archopht.1979.01020010312004

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  12 in total

1.  Comparative study on the combined effects of bunazosin and nipradilol or timolol on intraocular pressure in normotensive rabbits.

Authors:  Masahiro Orihashi; Yuichiro Shima; Hiroshi Tsuneki; Ikuko Kimura
Journal:  Jpn J Ophthalmol       Date:  2005 Nov-Dec       Impact factor: 2.447

2.  The effect of trabeculectomy on intraocular pressure of the untreated fellow eye in the collaborative initial glaucoma treatment study.

Authors:  Nathan M Radcliffe; David C Musch; Leslie M Niziol; Jeffrey M Liebmann; Robert Ritch
Journal:  Ophthalmology       Date:  2010-06-08       Impact factor: 12.079

3.  The contralateral reduction of intraocular pressure by timolol.

Authors:  C N Dunham; R F Spaide; G Dunham
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

4.  Blind randomised non-crossover long-term trial comparing topical timolol 0.25% with timolol 0.5% in the treatment of simple chronic glaucoma.

Authors:  K B Mills
Journal:  Br J Ophthalmol       Date:  1983-04       Impact factor: 4.638

5.  Effects of long-term treatment with timolol on lacrimal gland function.

Authors:  R L Coakes; I A Mackie; D V Seal
Journal:  Br J Ophthalmol       Date:  1981-09       Impact factor: 4.638

6.  Effects of timolol on corneal sensitivity and tear production.

Authors:  Y Kitazawa; H Tsuchisaka
Journal:  Int Ophthalmol       Date:  1980-12       Impact factor: 2.031

7.  Effect of Timolol on Aqueous Humor Outflow Facility in Healthy Human Eyes.

Authors:  Arash Kazemi; Jay W McLaren; Matthew G J Trese; Carol B Toris; Vikas Gulati; Shan Fan; David M Reed; Tyler Kristoff; Jesse Gilbert; Sayoko E Moroi; Arthur J Sit
Journal:  Am J Ophthalmol       Date:  2019-02-19       Impact factor: 5.258

8.  Short-term and long-term timolol maleate effects on corneal sensitivity.

Authors:  D Spinelli; F Vigasio; P Montanari
Journal:  Doc Ophthalmol       Date:  1984-02-29       Impact factor: 2.379

Review 9.  Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products.

Authors:  Gábor Holló; Jouni Vuorinen; Juhani Tuominen; Teppo Huttunen; Auli Ropo; Norbert Pfeiffer
Journal:  Adv Ther       Date:  2014-09-12       Impact factor: 3.845

10.  Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenon.

Authors:  Jie Shen; Marina Bejanian
Journal:  Clin Ophthalmol       Date:  2016-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.